Antithrombotic Drugs Have A Minimal Effect on Intraoperative Blood Loss During Emergency Surgery for Generalized Peritonitis: A Nationwide Retrospective Cohort Study In Japan

Tadashi Matsuoka (✉ tadashi_matsuoka1984@yahoo.co.jp)
Keio University  https://orcid.org/0000-0002-3837-8960

Nao Ichihara
Tokyo University Graduate School

Hiroharu Shinozaki
Saiseikai Utsunomiya Hospital

Kenji Kobayashi
Saiseikai Utsunomiya Hospital

Alan Kawarai Lefor
Jichi Medical University

Toshimoto Kimura
Iwate Medical University

Yuko Kitagawa
Japanese Society of Gastroenterological Surgery

Yoshihiro Kakeji
Japanese Society of Gastroenterological Surgery

Hiroaki Miyata
Tokyo University

Junichi Sasaki
Keio University

Research Article

Keywords: Emergency gastrointestinal surgery, Generalized peritonitis, Antithrombotic drug, Intraoperative blood loss.

DOI: https://doi.org/10.21203/rs.3.rs-409213/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background:

The effect of antithrombotic drugs on intraoperative operative blood loss volume in patients undergoing emergency surgery for generalized peritonitis is not well defined. The purpose of this study is to evaluate whether antithrombotic drugs affect intraoperative blood loss in generalized peritonitis using a nationwide surgical registry in Japan.

Method:

This retrospective cohort study used a nationwide surgical registry data from 2011 to 2017 in Japan. Propensity score matching for the use of antithrombotic drugs was used for the adjustment of age, gender, comorbidities, frailty, preoperative patient's state, types of surgery, surgical approach, laboratory data, and others. The main outcome was intraoperative blood loss: comparison of intraoperative blood loss; adjusted ratio of intraoperative blood loss after adjustment for confounding factors; variable importance of all covariates.

Results:

A total of 70,105 of the eligible 75,666 patients were included in this study, and 2,947 patients were taking antithrombotic drugs. Propensity score matching yielded 2,864 well-balanced pairs. There was a statistically difference in the blood loss. (antithrombotic drugs vs control: 100 [10-349] vs 70 [10-299] ml, p<0.01). After adjustment for confounding factors, the use of antithrombotic drugs was related to a 1.30-fold increase in intraoperative blood loss compared to non-use of antithrombotic drugs (95% CI, 1.16 – 1.45). The variable importance revealed that the effect of the use of antithrombotic drugs was minimal compared with surgical approach or type of surgery.

Conclusion:

This study shows that while taking antithrombotic drugs is associated with a slight increase in intraoperative blood loss in emergency surgery for generalized peritonitis, the difference is negligible and not clinically significant.

Background

The number of patients taking antithrombotic (AT) drugs is increasing along with the aging population[1]. Surgeons are more often facing situations when they have to operate on patients taking AT drugs. Emergency surgery for generalized peritonitis, which may frequently be associated with sepsis and coagulopathy, is associated with a high risk of perioperative complications, reportedly about 40 ~ 50 % [2–4]. When considering surgery for patients with generalized peritonitis who also take AT drugs, there is always concern about increased intraoperative blood loss, postoperative hemorrhage and thrombotic complications.
Clinical guidelines are inconclusive regarding the management of AT drugs for patients undergoing noncardiac surgery.[5–8]. Many reports are based on studies with a small sample size or retrospective data, which may not allow conclusive statements. We previously reported that the use of AT drugs was not significantly associated with increased intraoperative blood loss in emergency gastrointestinal surgery in a single-institution study of 170 patients taking AT drugs[9]. However, including that study, there are no large-scale cohort or randomized studies to clarify the effect of AT drugs on blood loss. There are no studies to date to definitively conclude that the use of AT drugs does not affect intraoperative blood loss, perioperative hemorrhagic or thrombotic complications in patients undergoing emergency surgery for generalized peritonitis.

The purpose of this study was to evaluate whether taking AT drugs had an effect on intraoperative blood loss in patients with generalized peritonitis using a nationwide patient registry in Japan. This information is of great importance to surgeons who perform emergency gastrointestinal surgery. Based on the results of our previous study, we hypothesized that the use of AT drugs was not associated with increased intraoperative blood loss in patients undergoing emergency surgery for generalized peritonitis.

**Methods**

**Study design and population**

This retrospective observational study used data from the National Clinical Database (NCD), which is a nationwide surgical registry in Japan that contains data on perioperative clinical characteristics and outcomes. Inclusion criteria for this study were defined as patients undergoing emergency surgery for acute generalized peritonitis from 2011 to 2017. The AT drug group was defined as patients who take AT drugs including either antiplatelet drugs or anticoagulant drugs, regardless of the use of antidotes. Data for patients with a missing value in any of the following fields were excluded: the use of AT drugs, intraoperative blood loss, date of surgery, age, or gender. Data for patients with less frequently performed procedures including highly invasive procedures such as esophagectomy or pancreatotomy, surgery for non-gastrointestinal diseases, two or more major procedures in the same operation (e.g., gastrectomy and colectomy, concurrently), or surgery for trauma was excluded. This study was approved by the Institutional Review Board of Saiseikai Utsunomiya Hospital (No.2018-15). This study is reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines[10].

**Outcomes**

The primary outcome of this study was intraoperative blood loss. The relationship of the use of AT drugs to intraoperative blood loss was evaluated by the following three measures: comparison of intraoperative blood loss volume, adjusted ratio of intraoperative blood loss compared with non-use of AT drugs after adjustment for potential confounding variables, and the variable importance of all study variables including covariates. Intraoperative blood loss was quantified by measuring suction fluid and weighing surgical gauze used for blood and fluid collection, in which fluid other than blood such as ascites was
subtracted. Secondary outcomes were the incidence of severe intraoperative bleeding, defined as intraoperative blood loss of more than 1,000 ml, intraoperative transfusions, bleeding complications, thrombotic complications, and postoperative transfusions, in-hospital mortality, the rate of infectious complications, duration of surgery, intensive care unit (ICU) length of stay, and hospital length of stay.

**Covariates**

Potential confounders included demographic factors, comorbidities, the perioperative status of the patient, procedure performed, and laboratory data (Table 1 and Table S1). Procedures performed were classified into 1 of the 12 surgical procedures listed, using the classification which would most influence the intraoperative blood loss: peritoneal lavage, gastrectomy, patch repair of peptic ulcer, other gastric surgery, colorectal resection, other colorectal surgery, small bowel obstruction surgery, other small intestinal surgery, stoma creation, appendectomy, cholecystectomy, common bile duct surgery. Sepsis and septic shock were classified based on the sepsis-1 definition[11]. Coagulopathy was defined as both a platelet count less than $1.2 \times 10^5/\mu L$ and PT-INR more than 1.4. Acute kidney injury was defined as rapid exacerbation of creatinine to more than 3 mg/dl, as a change compared with 24-hours before surgery.
## Table 1
Demographic, Clinical and Surgical Characteristics

|                     | Before Matching |                  | After Matching |                  |
|---------------------|-----------------|------------------|----------------|------------------|
|                     | AT              | Control          | AT             | Control          |
| Subjects            | 2 947           | 67 158           | 2 864          | 2 864            |
| Age, years (range)  | 77 (69–84)      | 70 (57–80)       | 77 (69–84)     | 78 (68–84)       |
| Gender, Male        | 1 884 (63.9%)   | 40 067 (59.7%)   | 1 815 (63.3%)  | 1 795 (62.7%)    |
| Body mass index (kg/m²) | 21.5 (19.1–24.0) | 21.0 (18.7–23.6) | 21.5 (19.1–24.0) | 21.3 (19.0–23.9) |
| Comorbidities       |                 |                  |                |                  |
| Diabetes mellitus   | 767 (26.0%)     | 9 460 (14.1%)    | 732 (25.6%)    | 721 (25.2%)      |
| Myocardial infarction | 101 (3.4%)   | 296 (0.4%)       | 89 (3.1%)      | 77 (2.7%)        |
| Angina pectoris     | 172 (5.8%)      | 772 (1.1%)       | 150 (5.2%)     | 139 (4.9%)       |
| Congestive heart failure | 336 (11.4%) | 1 171 (1.7%)    | 299 (10.4%)    | 254 (8.9%)       |
| Hypertension        | 1 764 (59.9%)   | 21 452 (31.9%)   | 1 697 (59.3%)  | 1 681 (58.7%)    |
| Cerebrovascular disease | 572 (19.4%) | 2 644 (3.9%)    | 532 (18.6%)    | 523 (18.3%)      |
| COPD                | 189 (6.4%)      | 2 045 (3.0%)     | 179 (6.3%)     | 166 (5.8%)       |
| CKD with hemodialysis | 419 (14.2%) | 2 172 (3.2%)    | 388 (13.5%)    | 370 (12.9%)      |
| Advanced cancer with metastasis | 150 (5.1%) | 2 993 (4.5%)  | 148 (5.2%)     | 158 (5.5%)       |
| Long-term steroid use | 312 (10.6%) | 2 718 (4.0%)  | 292 (10.2%)    | 280 (9.8%)       |

Data are presented as number (percentage) or median (interquartile).

AT, antithrombotic drug group; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; PCI, percutaneous coronary intervention; ASA, American Society of Anesthesiologist.
| Past intervention history          | Before Matching | Standardized difference | After Matching | Standardized difference |
|-----------------------------------|-----------------|--------------------------|----------------|--------------------------|
|                                   | AT (13.3%)      | Control (1.7%)           |                | AT (12.0%)              | Control (10.4%)           |
| PCI                               | 393             | 1,123                    | -0.454         | 345                      | 299                       | -0.051                    |
| Cardiac surgery                   | 307 (10.4%)     | 853 (1.3%)               | -0.398         | 267 (9.3%)               | 224 (7.8%)                | -0.054                    |
| Peripheral vascular surgery       | 157 (5.3%)      | 295 (0.4%)               | -0.295         | 126 (4.4%)               | 96 (3.4%)                 | -0.054                    |
| Activities of daily living        |                 |                          | 0.429          |                          |                          | 0.005                     |
|                                   | Independent     |                          |                |                          |                          |                           |
|                                   | 1,901 (64.5%)   | 55,728                   |                | 1,873 (65.4%)            | 1,868 (65.2%)             |
|                                   | Partial dependent | 693 (23.5%)          |                | 656 (22.9%)              | 657 (22.9%)               |
|                                   | Complete dependent | 353 (12.0%)         |                | 335 (11.7%)              | 339 (11.8%)               |
|                                   | Smoking history | 397 (13.5%)             | 14,288 (21.3%) | 388 (13.5%)              | 394 (13.8%)               | 0.006                     |
|                                   | Drinking history | 1,083 (36.8%)         | 27,307 (40.7%) | 1,046 (36.5%)            | 1,025 (35.8%)             | -0.016                    |
|                                   | Preoperative state |                 |                |                          |                           |                           |
|                                   | Severe Sepsis/ Septic shock | 614 (20.8%) | 5,981 (8.9%) | 0.506                   | 579 (20.2%)               | 558 (19.5%)               | 0.024                     |
|                                   | Coagulopathy    | 201 (7.2%)              | 1,209 (1.9%)   | -0.258                   | 163 (6.0%)                | 163 (6.0%)                | -0.002                    |
|                                   | Acute kidney injury | 324 (11.0%)      | 2,202 (3.3%)   | -0.303                   | 305 (10.6%)               | 287 (10.0%)               | -0.021                    |
|                                   | Mechanical ventilation | 241 (8.2%) | 1,957 (2.9%) | -0.232                   | 226 (7.9%)                | 220 (7.7%)                | -0.008                    |
|                                   | Performance status |              |                | 0.717                    |                           | 0.026                     |

Data are presented as number (percentage) or median (interquartile).

AT, antithrombotic drug group; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; PCI, percutaneous coronary intervention; ASA, American Society of Anesthesiologist.
| Before Matching | After Matching |
|-----------------|---------------|
|                 | AT | Control | Standardized difference |
|                 | AT | Control | Standardized difference |
| ASA-1E          | 53 (1.8%) | 10 540 (15.7%) | 53 (1.9%) | 60 (2.1%) |
| ASA-2E          | 685 (23.2%) | 26 256 (39.1%) | 681 (23.8%) | 702 (24.5%) |
| ASA-3E          | 1 506 (51.1%) | 22 219 (33.1%) | 1 460 (51.0%) | 1 437 (50.2%) |
| ASA-4E          | 512 (17.4%) | 6 035 (9.0%) | 491 (17.1%) | 488 (17.1%) |
| ASA-5E          | 191 (6.5%) | 2 102 (3.1%) | 179 (6.3%) | 175 (6.1%) |
| Type of surgery | 0.300 | 0.000 |
| Peritoneal lavage | 906 (30.7%) | 22 468 (33.5%) | 890 (31.1%) | 890 (31.1%) |
| Gastrectomy     | 17 (0.6%) | 583 (0.9%) | 14 (0.5%) | 14 (0.5%) |
| Patch repair of peptic ulcer | 161 (5.5%) | 7 353 (10.9%) | 157 (5.5%) | 157 (5.5%) |
| Other gastric surgery | 9 (0.3%) | 226 (0.3%) | 8 (0.3%) | 8 (0.3%) |
| Colorectal resection | 649 (22.0%) | 11 150 (16.6%) | 636 (22.2%) | 636 (22.2%) |
| Other colorectal surgery | 34 (1.2%) | 708 (1.1%) | 33 (1.2%) | 33 (1.2%) |
| Small bowel obstruction surgery | 31 (1.1%) | 588 (0.9%) | 29 (1.0%) | 29 (1.0%) |
| Other small intestinal surgery | 357 (12.1%) | 5 980 (8.9%) | 344 (12.0%) | 344 (12.0%) |
| Stoma creation | 476 (16.2%) | 10 002 (14.9%) | 466 (16.3%) | 466 (16.3%) |
| Appendectomy   | 206 (7.0%) | 6 852 (10.2%) | 194 (6.8%) | 194 (6.8%) |

Data are presented as number (percentage) or median (interquartile).

AT, antithrombotic drug group; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; PCI, percutaneous coronary intervention; ASA, American Society of Anesthesiologist.
| Before Matching | After Matching |
|-----------------|---------------|
|                | AT | Control | Standardized difference | AT | Control | Standardized difference |
| Cholecystectomy | 92 (3.1%) | 1 089 (1.6%) | 85 (3.0%) | 85 (3.0%) |
| Common bile duct surgery | 9 (0.3%) | 159 (0.2%) | 8 (0.3%) | 8 (0.3%) |
| Surgical approach | 0.193 | -0.037 |
| Laparotomy       | 2 688 (91.2%) | 57 074 (85.0%) | 2 611 (91.2%) | 2 640 (92.2%) |
| Laparoscopy      | 259 (8.8%) | 10 084 (15.0%) | 253 (8.8%) | 224 (7.8%) |
| Surgery for cancer | 258 (8.8%) | 6 822 (10.2%) | 256 (8.9%) | 276 (9.6%) |
| Hospital volume (procedure/year) | 78 (40–149) | 78 (38–148) | 78 (40–149) | 82 (40–152) |

Data are presented as number (percentage) or median (interquartile).

AT, antithrombotic drug group; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; PCI, percutaneous coronary intervention; ASA, American Society of Anesthesiologist.

**Statistical analysis**

**Descriptive and bivariate analysis**

All variables are expressed as the median (interquartile range (IQR)) or proportions. Baseline characteristics were compared between the AT drug group and the control group by standardized differences, and outcomes were compared using the Mann-Whitney U test and Pearson's Chi-square test.

**Propensity score matching**

Propensity score was calculated as predicted probability of having received AT drugs preoperatively using a logistic regression model, with all covariates listed in Table 1 and Table S1 as independent variables, on the entire analysis dataset. Assuming balance in types of surgery and coagulopathy is of particular importance, exact matching was applied to stratify patients by these variables, followed by nearest neighbor matching within each subgroup, with a caliper of standard deviation of the propensity score multiplied by 0.25. Matching was evaluated and optimized using standardized differences as the primary measure of covariate balance.

Regression-adjusted relationship of AT drugs and the intraoperative blood loss
Multivariable regression was applied in the matched cohort. The use of AT drugs and all covariates were used as independent variables. Using log-transformation of intraoperative blood loss, the ratio of AT drug to control groups, adjusted for other covariates, was obtained.

Variable importance

Permutation variable importance, defined as a decrease in the model accuracy caused by permutation of each independent variable, was calculated to examine the relative importance of AT drugs in affecting intraoperative blood loss compared to other covariates [12, 13]. A random forest model with 1,000 trees using all the independent variables was fitted for log-transformed intraoperative blood loss (ml), with zero (0) replaced with one (1).

Statistical analysis was performed by R software (version 4.0.2, 2020; R Foundation for Statistical Computing, Vienna, Austria). JMP® Pro software version 15.2.0 was also used for comparison of variables between groups (SAS Institute Inc., USA, 2020). All p-values were two-sided and p-values less than 0.05 were considered statistically significant. Details in statistical analysis was described in Additional file 1.

Results

Patient characteristics

During the study period 75,666 patients underwent emergency surgery for generalized peritonitis. After applying exclusion criteria (5,561 patients), 70,105 patients remained and were analyzed as an unmatched cohort. Of these, 2,947 patients (4.2%) were taking AT drugs at the time of emergency surgery. Propensity score matching selected 2,864 patients who used AT drugs and 2,864 patients who did not (Fig. 1, Additional file 2). Demographic, clinical and surgical characteristics before and after propensity score matching are shown in Table 1. The etiologies of generalized peritonitis are shown in Additional file 3. Before matching, patients taking AT drugs were older and had more comorbidities such as diabetes mellitus, coronary artery disease, cerebrovascular disease, and hypertension. More patients taking AT drugs also have a previous history of interventions related to cardiovascular diseases such as percutaneous coronary intervention, cardiac surgery, and peripheral vascular surgery. Preoperatively, sepsis and septic shock, and coagulopathy were seen more frequently in the AT group, and performance state was lower compared to the control group before matching. There were relatively large differences in the distribution of the types of surgical procedures performed before matching. Patients taking AT drugs were more likely to have undergone surgery of the small intestine or colon/rectum compared with patients taking no AT drugs, while patients taking no AT drugs were more likely to have undergone surgery of the stomach or appendix. Open laparotomy approach was more commonly performed for patients undergoing emergency gastrointestinal procedures on patients taking AT drugs. After matching, variables such as age, gender, comorbidities, types of surgery, and surgical approach were well balanced.
between the two groups. There were no laboratory data variables, which are included in the propensity score matching, with a standardized difference > 0.1 after matching (Additional file 4).

**Primary outcome:**

Intraoperative blood loss in patients taking AT drugs

Before matching, intraoperative blood loss in the AT drug group was significantly greater than in the control group (the AT drug group vs the control group, median (IQR): 100 (350–10) vs 50 (200–5) ml, p < 0.0001). After matching, intraoperative blood loss in the AT drug group was significantly greater than in the control group (100 (349–10)) vs 70 (299–10) ml, p = 0.0001) (Table 2, Fig. 2). The distribution of intraoperative blood loss by type of procedure and the differences due to taking AT drugs are shown in Additional file 5. Colon/rectal surgery and cholecystectomy had more blood loss while patch repair of peptic ulcer and appendectomy had less. For each type of procedure, the difference between the AT drug group and the control group was smaller than their interquartile ranges.

Table 2
The differences and the adjusted ratio of intraoperative blood loss

|                      | AT            | Control       | P value |
|----------------------|---------------|---------------|---------|
| Subjects             | 2 864         | 2 864         |         |
| Intraoperative blood loss (ml) | 100 (10–349) | 70 (10–299)  | 0.0001  |
|                      | Estimate (95% CI) | P value     |         |
| The Adjusted ratio of the intraoperative blood loss* | 1.30 (1.16–1.45) | < 0.0001   |         |

Data are presented as median (interquartile).

AT, antithrombotic drug group; 95% CI, 95% confidential interval.

*: Compared with non-use of the anti-thrombotic drugs after adjustment for potential confounding variables.

Adjusted ratio of intraoperative blood loss compared with not taking AT drugs

After adjustment for potential confounding variables by regression analysis in matched patients, taking AT drugs was related to a 1.30-fold increase in intraoperative blood loss compared with not taking AT drugs (95% confidence interval, 1.16–1.45) (Table 2).

The variable importance of AT drugs

Permutation variable importance in an unmatched cohort suggested that type of surgical procedure and surgical approach have the highest impact on intraoperative blood loss among the explanatory variables. The impact of AT drugs was modest compared with type of surgery and surgical approach (Fig. 3). The distribution of intraoperative blood loss according to surgery type and surgical approach is shown in Fig. 4A. Surgery type such as colorectal surgery or cholecystectomy, and open laparotomy approach were
related to more intraoperative blood loss. The distribution of intraoperative blood loss stratified by the use of AT drugs or not for every type of surgery was similar (Fig. 4B).

Secondary outcomes

Bleeding and thrombosis related surgical outcomes

Table 3 and Additional file 6 show the relationship of taking AT drugs and other outcomes examined. Before matching, variables such as the rate of bleeding and thrombotic complications, the rate of intraoperative and postoperative blood transfusions, and the rate of severe bleeding were higher among patients taking AT drugs than in the control group. After matching, variables such as the incidence of bleeding complications, and the rate of intraoperative and postoperative blood transfusions were statistically significantly higher among patients taking AT drugs. There were no significant differences in other variables such as the rate of thrombotic complications or occurrence of severe bleeding between the two groups.
Table 3
Secondary outcomes

|                                | AT       | Control  | Relative risk | 95% confidential interval | P value |
|--------------------------------|----------|----------|---------------|----------------------------|---------|
| Subjects                       | 2 864    | 2 864    |               |                            |         |
| Bleeding and thrombosis-related surgical outcomes |          |          |               |                            |         |
| Intraoperative severe bleeding*| 229 (8.0%) | 194 (6.8%) | 1.18          | 0.98–1.42                  | 0.0770  |
| Intraoperative transfusion     | 1 020 (35.6%) | 865 (30.2%) | 1.18          | 1.09–1.27                  | <0.0001 |
| Bleeding complication          | 145 (5.1%) | 110 (3.8%) | 1.32          | 1.03–1.68                  | 0.0249  |
| Thrombotic complication        | 127 (4.4%) | 102 (3.6%) | 1.25          | 0.96–1.61                  | 0.0918  |
| Post-operative transfusion     | 711 (24.8%) | 625 (21.8%) | 1.14          | 1.04–1.25                  | 0.0072  |
| Other postoperative outcomes   |          |          |               |                            |         |
| Mortality                      | 664 (23.2%) | 662 (23.1%) | 1.00          | 0.91–1.10                  | 0.9500  |
| Infectious complication        |          |          |               |                            |         |
| Severe sepsis/ septic shock    | 567 (19.8%) | 539 (18.8%) | 1.05          | 0.95–1.17                  | 0.3486  |
| Surgical site infection        | 880 (30.7%) | 837 (29.2%) | 1.05          | 0.97–1.14                  | 0.2149  |
| Pneumonia                      | 421 (14.7%) | 407 (14.2%) | 1.03          | 0.91–1.17                  | 0.5989  |
| Urinary tract infection        | 116 (4.1%) | 109 (3.8%) | 1.06          | 0.82–1.38                  | 0.6340  |
| Duration of operation (minutes)| 129 (95–175) | 125 (92–168) | -             | -                          | 0.0306  |
| ICU length of stay             | 5 (3–11)  | 5 (3–11)  | -             | -                          | 0.8911  |
| Hospital length of stay        | 31 (16–54) | 32 (18–57) | -             | -                          | 0.1070  |

Data are presented as number (percentage) or median (interquartile).

AT, antithrombotic drug group; ICU, intensive care unit.

* Intraoperative severe bleeding was defined as intraoperative blood loss of more than 1000 ml.
Before matching, variables such as mortality, duration of operation, length of stay, and the rate of infectious complications (surgical site infection and pneumonia) were higher among patients taking AT drugs compared to the control group. After matching, only the duration of surgery was higher among patients taking AT drugs (Table 3). There were no significant differences in other variables including mortality, length of stay, or rate of infectious complications between the two groups.

Discussion

We previously reported no significant difference in intraoperative blood loss after adjustment for confounding factors by propensity score matching in patients taking AT drugs undergoing emergency gastrointestinal surgery in a single institution[9]. In this study with a nationwide large-scale cohort, we focused on patients with generalized peritonitis, which needed surgical intervention immediately and was frequently accompanied by septic shock and coagulopathy. While this study shows a statistically significant increase in blood loss in patients taking AT drugs, the difference is minimal and likely of no clinical significance. AT drugs had a minimal influence on intraoperative blood loss in patients undergoing emergency surgery for generalized peritonitis after adjustment for confounding factors by propensity score matching. To the best of our knowledge, this is the first report to demonstrate safety for patients taking AT drugs with regard to perioperative bleeding and thrombotic complications, who undergo emergency gastrointestinal surgery for generalized peritonitis.

There is a wide range of opinions about the perioperative use of AT drugs. The American College of Surgeons’ guideline recommends cessation of aspirin for 7 to 10 days before procedures with a high risk for bleeding such as gastrointestinal surgery[5], while the Society of Thoracic Surgeons guidelines recommends continuation of aspirin monotherapy in patients undergoing non-cardiac surgery[6]. The difference in the guidelines is at least partially due to the low quality of available evidence[14–18]. The incidence of difficulty obtaining intraoperative hemostasis is rarely mentioned in existing studies. The present study results shows that AT drugs were not related to difficult intraoperative hemostasis during emergency surgery for generalized peritonitis because the increase in intraoperative blood loss and rate of blood transfusions was not clinically significant although it was statistically significant. Due to study design in patients undergoing emergency surgery, a randomized controlled study cannot be carried out. The results of this nationwide study have important implications for the clinical management of patients taking AT drugs who undergo emergency gastrointestinal surgery.

Generalized peritonitis is frequently associated with systemic sepsis and is considered by some to make operative procedures more complicated, with increased blood loss due to widespread inflammation[2, 19, 20]. Increased intraoperative blood loss has unfavorable effects on immune function[21–23], and is associated with major complications or a worse prognosis[24, 25]. When performing gastrointestinal surgery on patients with generalized peritonitis, surgical outcomes including intraoperative blood loss, mortality and postoperative morbidities, tend to be worse compared to performing surgery on patients without generalized peritonitis[26, 27]. This study shows that in patients with generalized peritonitis, the
effect of taking AT drugs on intraoperative blood loss and rate of blood transfusions was minimal and any increased risk of postoperative bleeding and thrombotic related complications was acceptable.

In this study, several methods of analysis gave similar results to support the conclusion that the effect of taking AT drugs was minimal. The type of surgical procedure or surgical approach, which have a high impact on intraoperative blood loss in this study, were reported as important factors associated with intraoperative blood loss in previous studies[28–31]. Therefore, less invasive procedures and surgical approach should be selected if there is no difference in mortality and morbidity expected for a particular patient. When selecting the procedure and surgical approach, taking AT drugs alone should not be a major factor in the decision-making process based on these results. For example, recent studies suggest that in patients with colorectal perforation, peritoneal lavage or laparoscopic surgery should be selected rather than open resection, if the situation permits, with no significant differences in mortality or the rate of serious complications between these procedures and surgical approaches[32–34]. Surgeons should manage patients with generalized peritonitis balancing the surgical curability of the disease and the feasibility of the selected procedure and surgical approach, and do not need to place undue emphasis on the use of AT drugs in some patients.

This study has acknowledged limitations. First, this study includes patients who take all types of AT drugs including antiplatelet drugs and anticoagulant drugs because the database used in this study does not distinguish among the types of AT drugs. Different mechanisms may confer different effects on intraoperative blood loss. Second, although propensity score matching is used to decrease the bias between the two groups, this study is retrospective and not blinded. Third, safety as an outcome is hard to quantify. We judged the primary outcome of this study as not clinically significant and safety because the differences in relative risks of outcomes are minimal though statistically significant. Fourth, the use of antidotes and the timing of restarting AT drugs was at the discretion of the primary surgeon, and are unknown in this study. Although the exact number of patients given vitamin K, which needs some time to normalize the PT-INR, is unknown, it would likely not be effective as an antidote for emergency surgery. Prothrombin complex concentrate and antidotes of direct oral anticoagulant were not approved yet in Japan during the study period. Therefore, we believe the effect of antidotes on the results of this study are minimal. Finally, the judgment to perform the operation and the choice of procedure is at the discretion of the individual surgeon, which could result in bias. For a patient taking AT drugs with a high risk of bleeding, surgeons might choose a less invasive procedure, or non-operative therapy, which they would not choose if the patient did not take AT drugs.

Conclusion

This study revealed that while patients taking AT drugs have increased intraoperative blood loss during emergency surgery for generalized peritonitis, the difference is minimal and not likely of no clinical significance. Therefore, surgery for patients taking AT drugs with generalized peritonitis can be performed safely although the use of AT drugs and must be taken into consideration, with individualized management according to the individual condition and procedural risk stratification.
Abbreviations

AT
Antithrombotic
NCD
National Clinical Database
ICU
Intensive care unit
IQR
Interquartile range

Declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Saiseikai Utsunomiya Hospital (No.2018-15). The requirement for obtaining informed consent from patients was waived because the data sets were anonymous.

Consent for publication

Informed consent was waived because of the anonymous nature of the data.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

T.M., H.S., K.K., A.K.L., T.K., Y.K., Y.K., and J.S. declare no competing interests.

N.I. and H.M. are affiliated with the Department of Healthcare Quality Assessment, which is a social collaboration department at the University of Tokyo supported by National Clinical Database, Johnson & Johnson K.K., and Nipro corporation.

Funding

This study was supported by a grant from the Japanese Society for Abdominal Emergency Medicine. The funding source had no role in the design, practice, or analysis of this study.

Authors’ Contributions
T.M. contributed to this article through study design, data collection, data analysis and interpretation, and article writing. N.I. contributed to statistical analysis, data interpretation and critical revisions of the article. H.S., K.K and A.K.L. contributed to data interpretation and critical revisions of the article. T.K., Y. Kitagawa, Y. Kakeji and H.M. contributed to study design. J.S. were involved in study design, data interpretation, and article review.

Acknowledgement

Not applicable.

References

1. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786 e1–10.

2. Bridoux V, Regimbeau JM, Ouaissi M, Mathonnet M, Mauvais F, Houivet E, et al. Hartmann's Procedure or Primary Anastomosis for Generalized Peritonitis due to Perforated Diverticulitis: A Prospective Multicenter Randomized Trial (DIVERTI). J Am Coll Surg. 2017;225:798–805.

3. Lambrichts DPV, Vennix S, Musters GD, Mulder IM, Swank HA, Hoofwijk AGM, et al. Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial. Lancet Gastroenterol Hepatol. 2019;4:599–610.

4. Binda GA, Karas JR, Serventi A, Sokmen S, Amato A, Hydo L, et al. Primary anastomosis vs nonrestorative resection for perforated diverticulitis with peritonitis: a prematurely terminated randomized controlled trial. Colorectal Dis. 2012;14:1403–10.

5. Hornor MA, Duane TM, Ehlers AP, Jensen EH, Brown PS Jr, Pohl D, et al. American College of Surgeons' Guidelines for the Perioperative Management of Antithrombotic Medication. J Am Coll Surg. 2018;227:521 – 36 e1.

6. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB, et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg. 2012;94:1761–81.

7. Society of Thoracic Surgeons Blood Conservation Guideline Task Force. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–82.

8. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology. 2015;122:241–75.
9. Matsuoka T, Kobayashi K, Lefor AK, Sasaki J, Shinozaki H. Antithrombotic drugs do not increase intraoperative blood loss in emergency gastrointestinal surgery: a single-institution propensity score analysis. World J Emerg Surg. 2019;14:63.

10. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–8.

11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644-55.

12. Breiman L. Random forests. Mach Learn. 2001;45:5–32.

13. Altmann A, Tolosi L, Sander O, Lengauer T. Permutation importance: a corrected feature importance measure. Bioinformatics. 2010;26:1340–7.

14. Oscarsson A, Gupta A, Fredrikson M, Jarhult J, Nyström M, Pettersson E, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104:305–12.

15. Mantz J, Samama CM, Tubach F, Devereaux PJ, Collet JP, Albaladejo P, et al. Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non-cardiac surgery: the multicentre, randomized, blinded, placebo-controlled, STRATAGEM trial. Br J Anaesth. 2011;107:899–910.

16. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257:399–414.

17. Columbo JA, Lambour AJ, Sundling RA, Chauhan NB, Bessen SY, Linshaw DL, et al. A Meta-analysis of the Impact of Aspirin, Clopidogrel, and Dual Antiplatelet Therapy on Bleeding Complications in Noncardiac Surgery. Ann Surg. 2018;267:1–10.

18. Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014;370:1494–503.

19. Menichetti F, Sganga G. Definition and classification of intra-abdominal infections. J Chemother. 2009;21(Suppl 1):3–4.

20. Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9:37.

21. Dhar DK, Kubota H, Tachibana M, Kotoh T, Tabara H, Watanabe R, et al. Long-term survival of transmural advanced gastric carcinoma following curative resection: multivariate analysis of prognostic factors. World J Surg. 2000;24:588 – 93; discussion 93 – 4.

22. Liang YX, Guo HH, Deng JY, Wang BG, Ding XW, Wang XN, et al. Impact of intraoperative blood loss on survival after curative resection for gastric cancer. World J Gastroenterol. 2013;19:5542–50.
23. Bruns CJ, Schafer H, Wolfgarten B, Engert A. [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]. Langenbecks Arch Chir Suppl Kongressbd. 1996;113:146–9.

24. Ejaz A, Gani F, Frank SM, Pawlik TM. Improvement of the Surgical Apgar Score by Addition of Intraoperative Blood Transfusion Among Patients Undergoing Major Gastrointestinal Surgery. J Gastrointest Surg. 2016;20:1752–9.

25. Mizuno A, Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, et al. Adverse Effects of Intraoperative Blood Loss on Long-Term Outcomes after Curative Gastrectomy of Patients with Stage II/III Gastric Cancer. Dig Surg. 2016;33:121–8.

26. Hoshino N, Endo H, Hida K, Ichihara N, Takahashi Y, Hasegawa H, et al. Emergency surgery for gastrointestinal cancer: A nationwide study in Japan based on the National Clinical Database. Ann Gastroenterol Surg. 2020;4:549–61.

27. Kakeji Y, Takahashi A, Hasegawa H, Ueno H, Eguchi S, Endo I, et al. Surgical outcomes in gastroenterological surgery in Japan: Report of the National Clinical Database 2011–2018. Ann Gastroenterol Surg. 2020;4:250–74.

28. Beyer K, Baukloh AK, Kamphues C, Seeliger H, Heidecke CD, Kreis ME, et al. Laparoscopic versus open gastrectomy for locally advanced gastric cancer: a systematic review and meta-analysis of randomized controlled studies. World J Surg Oncol. 2019;17:68.

29. Chaouch MA, Dougaz MW, Bouasker I, Jerraya H, Ghariani W, Khalfallah M, et al. Laparoscopic Versus Open Complete Mesocolon Excision in Right Colon Cancer: A Systematic Review and Meta-Analysis. World J Surg. 2019;43:3179–90.

30. Gonzalez R, Smith CD, Mattar SG, Venkatesh KR, Mason E, Duncan T, et al. Laparoscopic vs open resection for the treatment of diverticular disease. Surg Endosc. 2004;18:276–80.

31. Trastulli S, Cirocchi R, Listorti C, Cavaliere D, Avenia N, Gulla N, et al. Laparoscopic vs open resection for rectal cancer: a meta-analysis of randomized clinical trials. Colorectal Dis. 2012;14:e277-96.

32. Shaikh FM, Stewart PM, Walsh SR, Davies RJ. Laparoscopic peritoneal lavage or surgical resection for acute perforated sigmoid diverticulitis: A systematic review and meta-analysis. Int J Surg. 2017;38:130–7.

33. Schultz JK, Yaqub S, Wallon C, Blecic L, Forsmo HM, Folkesson J, et al. Laparoscopic Lavage vs Primary Resection for Acute Perforated Diverticulitis: The SCANDIV Randomized Clinical Trial. JAMA. 2015;314:1364–75.

34. Vennix S, Musters GD, Mulder IM, Swank HA, Consten EC, Belgers EH, et al. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial. Lancet. 2015;386:1269–77.
75,666 Patients underwent emergency surgery for generalized peritonitis from 2011-2017, extracted from the National Clinical Database

5,561 Excluded
- 2,849 Trauma etiology
- 1,072 Surgery for non-gastroenterological disease
- 630 Highly invasive surgery
- 561 Two or more procedures
- 449 Missing data for intraoperative blood loss

70,105 Included in study analysis
- 2,947 took antithrombotic drug(s) at the time of surgery
- 67,158 took no antithrombotic drugs

5,728 Propensity score matched
- 2,864 took antithrombotic drug(s) at the time of surgery
- 2,864 took no antithrombotic drugs

Figure 1

Study population.
Figure 2

Comparison of intraoperative blood loss for antithrombotic drug use (box plot). A: Before matching. B: After matching. *p < 0.05 compared with the control group as analyzed using Mann-Whitney U test. AT, antithrombotic drug group. The horizontal line in the middle of each box is the median; box length is the interquartile range; whiskers represent the range of the data within the 10th and 90th percentiles.

Figure 3

Relative importance of each covariate in predicting intraoperative blood loss by the variable importance method. Permutation variable importance was defined as a decrease in the model accuracy caused by permutation of an independent variable. All variables had statistically significant importance. eGFR, estimated glomerular filtration rate; BMI, body mass index; Cre, creatinine; PS-ASA, performance status classification by American Society of Anesthesiologist; ALT, alanine aminotransferase; CRP, C-reactive protein; ALP, alkaline phosphatase; BUN, blood urea nitrogen; APTT, activated partial thromboplastin time; AKI, acute kidney injury; ADL, activities of daily living; WBC, white blood cell; CKD, chronic kidney disease; AST, aspartate aminotransferase; CHF, congestive heart failure; Na, serum sodium; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention.
Figure 4

Distribution of intraoperative blood loss in the entire without matching. (A) By major procedure type and surgical approach. (B) By major procedure type and use of antithrombotic drugs. The horizontal line in the middle of each box is the median; box length is the interquartile range; whiskers represent the range of the data within the 10th and 90th percentiles.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.docx
- Additionalfile2.pdf
- Additionalfile3.docx
- Additionalfile4.docx
- Additionalfile5.docx
• Additionalfile6.docx